Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Envoy Medical (COCH) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Envoy Medical (COCH) over the last 4 years, with Q3 2025 value amounting to 15435.71%.

  • Envoy Medical's EBITDA Margin fell 47910700.0% to 15435.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 10474.52%, marking a year-over-year decrease of 28928600.0%. This contributed to the annual value of 9244.44% for FY2024, which is 2254900.0% up from last year.
  • Latest data reveals that Envoy Medical reported EBITDA Margin of 15435.71% as of Q3 2025, which was down 47910700.0% from 7297.44% recorded in Q2 2025.
  • In the past 5 years, Envoy Medical's EBITDA Margin ranged from a high of 1952.5% in Q3 2023 and a low of 57405.0% during Q4 2022
  • In the last 4 years, Envoy Medical's EBITDA Margin had a median value of 10644.64% in 2024 and averaged 13280.33%.
  • Per our database at Business Quant, Envoy Medical's EBITDA Margin surged by 522502600bps in 2023 and then tumbled by -125971400bps in 2024.
  • Over the past 4 years, Envoy Medical's EBITDA Margin (Quarter) stood at 57405.0% in 2022, then surged by 91bps to 5154.74% in 2023, then tumbled by -113bps to 11000.0% in 2024, then tumbled by -40bps to 15435.71% in 2025.
  • Its EBITDA Margin stands at 15435.71% for Q3 2025, versus 7297.44% for Q2 2025 and 10852.17% for Q1 2025.